Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vitamin d doses tested as COVID-19 shield in chicago study

NCT ID NCT04868903

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study looked at whether taking different amounts of vitamin D could lower the risk of getting COVID-19. About 1,475 adults from the Chicago area took either a low (400 IU), moderate (4,000 IU), or high (10,000 IU) daily dose of vitamin D for 9 months. Researchers tracked who got COVID-19 to see if higher doses offered more protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,475 people

The number who actually took part.

Started

Nov 2020

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Subjects are able to participate if they: 1. Are 18 years or older. 2. Live or work in the Chicagloland area (Illinois counties: Cook, Lake, McHenry, DuPage, Kane, Kendall, Grundy, Will, and Kankakee; Indiana counties: Lake and Porter). 3. Are interested in vitamin D as a potential preventive measure against COVID-19 in which they self-administer a daily dose of vitamin D during the 9-month study period. 4. Are willing to attend the laboratory for drop-in appointments at UChicago Medicine or Rush University Medical Center every 3 months at 4 time points over a 9-month period for blood draws measuring COVID-19 antibodies, calcium, vitamin D and PTH levels. 5. Are willing to complete self-report measures at 4 time points over the course of 9 months by completing a 15-minute survey at intake by telephone or via web and 10-minute web-based follow-up surveys. Subjects are excluded from study participation if they: 1. Report ever having a positive COVID-19 PCR test result 2. Report being pregnant, planning to become pregnant, and/or report breastfeeding during the study period. 3. Report a history of chronic kidney disease, including a history of abnormal GFR and/or creatinine. 4. Report a history of hyperparathyroidism. 5. Report a history of increased falls. 6. Report a history of hypercalcemia. 7. Report a history of gastrointestinal absorptive disorders, including having undergone bariatric surgery. 8. Report a history of kidney stones (1 in past year or 2 in lifetime). 9. Report already taking more than 400 IU of vitamin D daily as recommended by their health care provider, excluding multivitamins and excluding supplements that include vitamin D and calcium together. 10. Report taking D2. 11. Report a history of sarcoidosis. 12. Screen positive for hypercalcemia during the initial blood test or follow-up blood tests. 13. Screen positive for primary hyperparathyroidism during the initial blood test. 14. Screen positive for COVID-19 antibodies during the initial blood test. 15. Have vitamin D levels of \>100ng/mL at study start, or \>250ng/mL during follow-up labs. 16. Are unwilling to provide blood samples during quarterly blood tests. 17. Are unwilling to take daily vitamin D.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-CoV-2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • University of Chicago

    Chicago, Illinois, 60637-1622, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.